### External request:
Submission from Bayer HealthCare:
Request for addition of Xofigo® (radium Ra-223 dichloride) to the NCCN Guidelines for Castrate Resistant Prostate Cancer (CRPC) with bone metastasis.

### Panel Discussion
Based on the data in the noted reference and Panel discussion, the consensus was to include radium-223 as a first-line or second-line therapeutic option for symptomatic bone metastases.

### References
Vogelzang N, et al. Updated analysis of radium 223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA). Poster presented at: American Society of Clinical Oncology, Genitourinary Cancers Symposium (ASCO GU); February 14-16, 2013; Orlando, FL.

### Vote

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vote</td>
<td>29</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>